Inclusion Criteria:

- Written informed consent must be obtained and documented according to the local
regulatory requirements prior to beginning specific protocol procedures

- Complete baseline documentation sent to GBG

- Age of at least 18 and at most 45 years

- Patients request to preserve ovarian function

- Spontaneous and regular menstrual periods before study entry with FSH below 15 mlU/ml
in follicular phase

- Histologically confirmed primary breast cancer with the need for anthracycline-based
chemotherapy

- Steroid receptor (estrogen and progesterone) negative tumor (diagnosis according to
hospital standard-procedures)

- No clinical evidence of local recurrence or distant metastases. Complete staging
work-up within 3 months prior to registration. All patients must have (bilateral)
mammography or breast MRI, chest X-ray; other tests may be performed as clinically
indicated

- Karnofsky-Index >80%

- Life expectancy of at least 10 years, disregarding the diagnosis of cancer

- Adequate organ function including normal red and white blood count, platelets, serum
creatinine, bilirubin, and transaminases within normal range of the institution

- Patients must be available for and compliant to treatment and follow-up. Patients
registered on this trial must be treated and followed up at the participating center.

Exclusion Criteria:

- Known hypersensitivity reaction to the investigational compounds or incorporated
substances

- Prior cytotoxic treatment for any reason

- Suspected (primary or secondary) ovarian insufficiency

- Pregnant or lactating patients. Patients of childbearing potential must have a
negative pregnancy test (urine or serum) within 14 days prior to registration and
must implement adequate non-hormonal contraceptive measures during study treatment;
prior use of hormonal contraceptives has to be discontinued before first Goserelin
injection

- Other serious illness or medical condition that may interfere with the understanding
and giving of informed consent and the conduct of the study

- Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or
carcinoma in situ of the uterine cervix)

- Concurrent treatment with other experimental drugs or any other anti-cancer therapy

- Concurrent treatment with sex hormones. Prior treatment must be stopped before study
entry